Navigation Links
Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Date:4/10/2008

BELLEVUE, WA, April 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from preclinical studies of PX-478, pharmacodynamic studies of PX-12 and preclinical studies of PX-866 will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego April 12-16, 2008.

Oncothyreon is currently conducting a Phase 1 clinical trial of PX-478 in patients with advanced metastatic cancer and a Phase 2 trial of PX-12 in patients with advanced pancreatic cancer. PX-866 is expected to enter a Phase 1 trial in patients with advanced cancers in the second quarter of 2008.

Details regarding these abstracts are as follows:

PX-478

- Molecular-genetic image guided studies of the antitumor HIF-1alpha

inhibitor PX-478 in combination with radiation

Abstract # 2566, Session: Novel Mechanisms of Drug Action

Presentation: Monday, April 14, 2008, 2:55 p.m. to 3:10 p.m. P.T.

- HIF-1alpha antagonism by PX-478 inhibits progression and spread of

orthotopic human small cell lung cancer and lung adenocarcinoma in

mice

Abstract # 1440, Session: mTOR/Akt/PI3K Inhibitors and

Vascular/Hypoxia Targeting Agents

Poster session: Sunday, April 13, 2008, 1:00 p.m. to

5:00 p.m. P.T.

PX-12

- Pharmacodynamic evaluation of plasma thioredoxin-1 for patient

enrichment of PX-12 clinical trials

Abstract # 4453, Session: Molecular Signatures and Proteomic

Biomarkers

Poster Session: Tuesday, April 15, 2008, 1:00 p.m. to

5:00 p.m. P.T.

PX-866

- Cellular and in vivo activity of a new PI3K inhibitor PX-866 for

treatment of human glioblastoma

Abstract # 3731, Session: Imaging in Preclinical and Clinical

Therapeutics

Poster Session: Tuesday, April 15, 2008, 8:00 a.m. to

12:00 p.m. PT

- Identification of novel synergistic targets RACK-1 and galectin-1 for

rational drug combinations with PI3 Kinase inhibitors using siRNA

synthetic lethality screening

Abstract # 2761, Session: Signal Transduction and Therapeutics

Poster Session: Monday, April 14, 2008, 1:00 p.m. to

5:00 p.m. P.T.

- Phosphatidylinositol 3-kinase stimulates the proliferation of

bronchioalveolar stem cells in mouse models of oncogenic K-ras-

induced lung cancer

Abstract # 5408, Session: Stem Cells

Poster Session: Wednesday, April 16, 2008, 8:00 a.m. to

12:00 p.m. P.T.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to future clinical development plans for PX-12 and PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12 and PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon announces effectiveness of shelf registration statement
2. Oncothyreon announces issuance of patent for PX-867
3. Oncothyreon to present at upcoming investment conferences
4. Oncothyreon reports full year and fourth quarter 2007 financial results
5. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
6. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
7. Oncothyreon launches new corporate website
8. Oncothyreon to present at BIO CEO & Investor Conference
9. Oncothyreon highlights corporate and clinical objectives for 2008
10. Biomira announces plan to change name to Oncothyreon
11. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2019)... ... January 15, 2019 , ... With the U.S. Congress designating January as Cervical Health Awareness ... service, today announces tips to help reduce the risk of Cervical Cancer. , Cervical ... HPV is the #1 most common STD and an STI that almost half ...
(Date:1/10/2019)... ... 08, 2019 , ... VGI Medical was founded in 2007 based on an ... to the market including VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems ... patented dual geometric design to limit motion of the affected spinal segment. Applying the ...
(Date:1/4/2019)... ... January 01, 2019 , ... uBiome, the leader in ... Forum Annual Meeting January 22-25, 2019 held in Davos-Klosters, Switzerland following their selection ... Forum Annual Meeting brings together leaders of global society–the heads and members of ...
(Date:12/19/2018)... FREDERICK, Md. (PRWEB) , ... December 19, 2018 ... ... solutions for Life Science, announces the validated release of Limfinity® version 7.1. The ... another important technical offering from RURO as 2018 comes to an end. , ...
Breaking Biology Technology:
(Date:12/18/2018)... ... 2018 , ... Nativis, Inc. , a clinical stage ... announced the publication of an early feasibility study in CNS Oncology suggesting that ... publication of the study, An Early Feasibility Study of the Nativis Voyager® Device ...
(Date:12/14/2018)... ... December 14, 2018 , ... ... entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by the US Patent ... 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary Apte, ...
(Date:12/13/2018)... Va. (PRWEB) , ... December 12, 2018 , ... ... that Dr. Vinod Shah, one of the firm’s prominent Expert Consultants, was recently ... Award. The award recognizes leaders who are working in pharmaceutical science, technology, engineering, ...
Breaking Biology News(10 mins):